Venus Remedies Limited (NSE: VENUSREM | BSE: 526953)

By Raveendran R | Updated on:

Source: Venus Remedies Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026)

Metrics for FY 2025-26 Ended Mar 31, 2026
Profit & Loss (₹ Cr)
Revenue
₹769.60 Cr (▲ 17.9%)
Prev Year: ₹652.89 Cr
Gross Profit
₹382.33 Cr (▲ 39.4%)
Prev Year: ₹274.27 Cr
Operating Profit
₹134.19 Cr (▲ 116.5%)
Prev Year: ₹61.98 Cr
Net Profit
₹102.79 Cr (▲ 126.9%)
Prev Year: ₹45.31 Cr
Ratios & Margins (% / x)
Gross Margin
49.68 % (▲ 767 bps)
Prev Year: 42.01 %
Operating Margin
17.44 % (▲ 794 bps)
Prev Year: 9.49 %
PAT Margin
13.36 % (▲ 642 bps)
Prev Year: 6.94 %
ROCE
19.39 % (▲ 870 bps)
Prev Year: 10.70 %
ROCE (3Y Avg)
14.85 %
FY24–FY26 (3Y Avg)
ROE
15.49 % (▲ 741 bps)
Prev Year: 8.08 %
ROE (3Y Avg)
10.17 %
FY24–FY26 (3Y Avg)
ROA
12.04 % (▲ 571 bps)
Prev Year: 6.33 %
Asset Turnover
0.90x (▼ 0.01 pts)
Prev Year: 0.91x
Balance Sheet (₹ Cr)
Total Assets
₹853.70 Cr (▲ 19.3%)
Prev Year: ₹715.72 Cr
Current Assets
₹395.20 Cr (▼ 0.4%)
Prev Year: ₹396.92 Cr
Total Liabilities
₹189.95 Cr (▲ 22.7%)
Prev Year: ₹154.77 Cr
Current Liabilities
₹161.76 Cr (▲ 18.7%)
Prev Year: ₹136.29 Cr
Total Equity
₹663.75 Cr (▲ 18.3%)
Prev Year: ₹560.95 Cr
Working Capital
₹233.44 Cr (▼ 10.4%)
Prev Year: ₹260.63 Cr
Ratios & Margins (% / x)
Current Ratio
2.44x (▼ 0.47 pts)
Prev Year: 2.91x
Equity Multiplier
1.29x (▲ 0.01 pts)
Prev Year: 1.28x
Cash Flow (₹ Cr)
Operating Cash Flow
₹155.77 Cr (▲ 80.2%)
Prev Year: ₹86.44 Cr
CapEx
₹37.66 Cr (▲ 291.1%)
Prev Year: ₹9.63 Cr
Free Cash Flow
₹118.11 Cr (▲ 53.8%)
Prev Year: ₹76.81 Cr
Ratios & Margins (% / x)
FCF Margin
15.35 % (▲ 358 bps)
Prev Year: 11.76 %
Cash ROCE
22.51 % (▲ 759 bps)
Prev Year: 14.92 %
Cash ROCE (3Y Avg)
14.42 %
FY24–FY26 (3Y Avg)
Cash ROE
23.47 % (▲ 806 bps)
Prev Year: 15.41 %
Cash ROE (3Y Avg)
14.91 %
FY24–FY26 (3Y Avg)

📋 Quick Facts: Company Snapshot

Attribute Disclosed Detail
Official Company Name Venus Remedies Limited
Corporate Identity Number (CIN) L24232CH1989PLC009705
ISIN INE411B01019
Stock Exchange Listing NSE: VENUSREM | BSE: 526953
Date of Incorporation / Founding Year 15th September, 1989
Founders / Key Founding Figures Pawan Chaudhary
Registered Office & Corporate Headquarters Registered Office: SCO 857, Cabin no. 10, 2nd Floor, NAC Manimajra, Chandigarh – 160101; Corporate Office: 51-52, Industrial Area, Phase-1, Panchkula – 134113, Haryana
Telephone & Official Investor Relations Email Phone: 0172-2933090, Fax: 0172-2565566 | Email: complianceofficer@venusremedies.com
Chairman / Managing Director & CEO Pawan Chaudhary (Chairman & Managing Director), Saransh Chaudhary (CEO – VMRC)
Chief Financial Officer (CFO) & Company Secretary (CS) Pawan Chaudhary (CFO), Neha Kodan (Company Secretary)
Promoter & Holding Group Pawan Chaudhary, Manu Chaudhary, and Sunev Pharma Solutions Private Limited
Industry / Sector Classification Pharmaceutical Industry (Specialized in Complex Injectables, Critical Care, and Anti-Infectives)
Total Employees / Workforce 1,472 Permanent Employees across 5 locations (16% female workforce)
Manufacturing Plants / Branches / Offices Count 3 Manufacturing Facilities (Panchkula, Baddi, and Werne/Hungary via subsidiaries)
Statutory, Secretarial & Cost Auditors M/s J.K. Jain & Associates (Statutory Auditors), M/s P. Chadha & Associates (Secretarial Auditors), M/s C. L. Bansal & Associates (Cost Auditors)
Registrar and Share Transfer Agent (RTA) MUFG Intime India Private Limited (formerly Link Intime India Private Limited), New Delhi

🏢 The Corporate Identity: Venus Remedies Overview, Promoters & History

The Big Picture: Business Model & Core Value Proposition

Venus Remedies Limited is a research-driven global pharmaceutical company specializing in complex injectable formulations, anti-infectives, oncology, critical care, and specialty therapies. Operating across more than 100 countries, the company combines robust manufacturing infrastructure with dedicated research capabilities anchored by the Venus Medicine Research Centre (VMRC). Its business model focuses on high-barrier sterile injectable products, antimicrobial resistance (AMR) mitigation, and proprietary drug delivery platforms, serving institutional, government, and private healthcare markets globally.

The Founders, Promoters & Their Legacy

The company is led by Pawan Chaudhary, Chairman and Managing Director, alongside co-founders and executive leaders including Dr. (Mrs.) Manu Chaudhary (Joint Managing Director & Director – Technical), Mr. Peeyush Jain, Mr. Ashutosh Jain, Mr. Akshansh Chaudhary, and Mr. Saransh Chaudhary. Over three decades, the founding leadership has steered Venus Remedies from a regional formulation player into an internationally recognized, research-driven institution holding over 150 global patents and more than 1,100 marketing authorisations.

The Journey: Corporate History & Key Milestones

Originally incorporated on September 15, 1989, as Venus Glucose Private Limited, the company progressively transitioned into complex injectables and critical care. Over subsequent decades, it established world-class manufacturing plants in Panchkula (Haryana) and Baddi (Himachal Pradesh), set up VMRC, expanded operations into Europe via German and Hungarian subsidiaries, and achieved major regulatory milestones including USFDA Qualified Infectious Disease Product (QIDP) designations for proprietary molecules such as VRP-034.

The Corporate Umbrella & Group Structure

The consolidated corporate structure comprises the holding company Venus Remedies Limited, its wholly owned foreign subsidiary Venus Pharma GmbH located in Werne, Germany, and a step-down subsidiary Venus Pharma Kft located in Hungary. Together, these entities form an integrated network for manufacturing, regulatory compliance, logistics, and international commercial distribution.

⚙️ The Business Engine: Segments, Brands, Products & Operations

The Core Divisions & Segment Revenue Breakdown

Venus Remedies derives its revenues primarily from pharmaceutical formulations categorized by therapeutic segments and geographic regions. The company operates in a single primary business segment: Pharmaceutical Formulations, engaging in the manufacture and distribution of specialized medicines.

Therapy / Segment Revenue (₹ Crores) % Share of Total Revenue
Antibiotics (Anti-Infectives) 443.51 57.63%
Anticancer (Oncology) 175.52 22.81%
Anticoagulant 39.97 5.19%
Analgesic 33.40 4.34%
Others / Specialty Therapies 77.20 10.03%
Total Revenue from Operations 769.60 100.00%

The Product & Service Catalog (with Operational KPIs & Order Book)

The company’s product portfolio exceeds 195+ formulations, backed by 700+ dossiers filed and 1,100+ global marketing authorisations. Key operational capabilities include a manufacturing capacity of 100 million injectable units per annum, hospital reach exceeding 12,000 institutions, and institutional supply chains spanning major government and private networks.

The Names You Know: Key Brands & Flagship Portfolio

Venus Remedies markets several established institutional and consumer brands across critical care, wound care, and natural wellness.

Brand / Product Name Category / Business Segment Target Market & Key Positioning
SUPIME Anti-Infective / Critical Care Advanced cephalosporin antibiotic positioned as a primary defense in severe hospital infections.
TROIS Analgesic / Pain Management Nanotechnology-based pain relief emulsion for targeted musculoskeletal care.
SEPTILOC Wound Care / Topical Specialized formulation for advanced wound management and infection control.
VENTAFUL A Respiratory / Specialty Care Therapeutic solution addressing COPD and asthma in hospital and clinical practice.
RESET Consumer Healthcare / Wellness Plant-based natural wellness and pain relief brand spanning topical oils and wellness accessories.

Mapping the Domestic & Global Reach (India vs. Exports)

International markets account for the majority of the company’s revenues, supported by a commercial presence across 100+ countries.

Geography / Region Revenue (₹ Crores) % Share of Total Revenue
India (Domestic) 178.45 23.19%
Latin America (LATAM) 142.78 18.55%
Europe 133.31 17.32%
Middle East 110.61 14.37%
Africa 99.30 12.90%
Asia (Ex-India) 94.64 12.30%
Others 10.51 1.37%
Total Consolidated Revenue 769.60 100.00%

The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices

The company operates 3 primary manufacturing units: Unit I at Panchkula (Haryana), Unit II at Baddi (Himachal Pradesh), and European operations through Venus Pharma GmbH (Germany) and Venus Pharma Kft (Hungary). R&D operations are concentrated at the DSIR-accredited Venus Medicine Research Centre (VMRC) in Baddi.

📊 The Financial Health: The Numbers Simplified

Multi-Year Financial Highlights (₹ in Crores)

Financial Metric (₹ Cr) FY 2025-26 FY 2024-25 FY 2023-24 Latest YoY (%)
Revenue from Operations 769.60 652.89 586.52 +17.88%
EBITDA (Operating Profit) 159.86 84.49 70.52 +89.21%
Profit After Tax (PAT) 102.79 45.31 33.90 +126.86%
Total Equity (Net Worth) 663.75 560.95 487.55 +18.33%
Net Operating Cash Flow 155.77 86.44 28.49 +80.21%

Earnings, Expenses, & Take-Take Profits (Consolidated Profit & Loss)

Consolidated P&L Line Item (₹ Crores) FY 2025-26 FY 2024-25 Latest YoY (%)
Revenue from Operations 769.60 652.89 +17.88%
Other Income 12.58 15.95 -21.13%
Total Income 782.18 668.84 +16.95%
Cost of Materials Consumed 387.98 348.77 +11.24%
Purchase of Stock-in-Trade 10.76 25.04 -57.03%
Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress (11.47) 4.81 N/M
Employee Benefit Expenses 88.68 80.49 +10.18%
Finance Costs 0.04 0.07 -42.86%
Depreciation and Amortization Expenses 25.67 22.51 +14.04%
Selling, Manufacturing & Administration Expenses 128.20 107.16 +19.63%
Research & Development Expenses 18.17 18.08 +0.50%
Total Expenses 648.03 606.93 +6.77%
Profit Before Tax & Exceptional Items 134.15 61.91 +116.69%
Exceptional Items 0.00 9.91 -100.00%
Profit Before Tax (PBT) 134.15 71.83 +86.76%
Tax Expenses (Current & Deferred) 31.36 26.51 +18.29%
Profit After Tax (PAT) 102.79 45.31 +126.86%
Other Comprehensive Income (OCI) 0.01 (0.68) N/M
Total Comprehensive Income 102.80 44.63 +130.34%

Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)

Consolidated Balance Sheet Line Item (₹ Crores) As at March 31, 2026 As at March 31, 2025 Latest YoY (%)
ASSETS
Property, Plant & Equipment 125.43 124.70 +0.59%
Capital Work-in-Progress (CWIP) 51.36 26.39 +94.62%
Intangible Assets & Right-of-Use Assets 106.17 104.72 +1.38%
Non-Current Investments & Financial Assets 171.56 60.52 +183.48%
Other Non-Current Assets 3.98 2.47 +61.13%
Total Non-Current Assets 458.50 318.81 +43.82%
Inventories 129.37 100.49 +28.74%
Current Investments 73.80 29.28 +152.05%
Trade Receivables 103.28 112.22 -7.97%
Cash and Cash Equivalents 25.12 57.52 -56.33%
Other Bank Balances & Financial Assets 5.02 23.44 -78.58%
Current Tax Assets & Other Current Assets 58.63 73.96 -20.73%
Total Current Assets 395.20 396.92 -0.43%
Total Assets 853.70 715.72 +19.28%
EQUITY AND LIABILITIES
Equity Share Capital 13.37 13.37 0.00%
Other Equity 650.38 547.58 +18.77%
Total Equity (Net Worth) 663.75 560.95 +18.33%
Provisions & Deferred Tax Liabilities (Non-Current) 17.15 18.48 -7.20%
Non-Current Lease Liabilities 11.05 0.00 N/M
Non-Current Borrowings 0.00 0.00 N/M
Total Non-Current Liabilities 28.20 18.48 +52.60%
Current Borrowings 0.00 1.69 -100.00%
Trade Payables (MSME & Others) 113.49 91.86 +23.55%
Current Lease Liabilities & Other Financial Liabilities 41.87 31.38 +33.43%
Other Current Liabilities & Provisions 6.40 11.35 -43.61%
Total Current Liabilities 161.76 136.29 +18.69%
Total Liabilities 189.95 154.77 +22.73%

Cash Flow: Tracking the Money Movement

Consolidated Cash Flow Statement (₹ Crores) FY 2025-26 FY 2024-25 Latest YoY (%)
Net Cash Generated from Operating Activities 155.77 86.44 +80.21%
Purchase of Property, Plant & Equipment (CapEx) 37.66 9.63 +291.07%
Net Cash Flow from Investing Activities (181.57) (76.25) +138.12%
Net Cash Flow from Financing Activities (3.12) (1.02) +205.88%
Net Increase / (Decrease) in Cash & Cash Equivalents (28.91) 9.18 N/M
Closing Cash & Cash Equivalents 25.12 57.52 -56.33%

Funding the Future: CapEx, CWIP, R&D & Foreign Exchange

Capital investments during the year included ₹37.66 Crores in property, plant, and equipment, while Capital Work-in-Progress (CWIP) stood at ₹51.36 Crores, reflecting ongoing capacity expansion in lyophilisation and sterile lines. Research and development expenditure amounted to ₹18.17 Crores on a standalone/consolidated operational basis (representing ~2.4% of turnover). Foreign exchange earnings stood at ₹416.86 Crores (USD 404.10M, EUR 141.58M, GBP 17.41M equivalent), while foreign exchange outgo was ₹44.52 Crores.

👥 Power & Control: Corporate Governance, Leadership & Ownership

The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)

Name of Director / KMP Designation / Role DIN Category
Pawan Chaudhary Chairman & Managing Director & CFO 00435503 Promoter, Executive
Dr. (Mrs.) Manu Chaudhary Joint Managing Director & Director – Technical 00435834 Promoter, Executive
Peeyush Jain Deputy Managing Director 00440361 Executive Director
Ashutosh Jain Executive Director (Administration & Law) 01336895 Executive Director
Akshansh Chaudhary Executive Director & Chief Technology Officer 08786627 Executive Director
Saransh Chaudhary Executive Director & CEO – VMRC 08752105 Executive Director
Navdeep Sud Independent Director 08764371 Non-Executive, Independent
Dr. (Mrs.) Savita Gupta Independent Director 08068504 Non-Executive, Independent
NPS Monga Independent Director 09339768 Non-Executive, Independent
Jagdish Chander Sharma Independent Director 00195489 Non-Executive, Independent
Dr. Anil Kumar Independent Director 10718262 Non-Executive, Independent
Dr. Gurminder Singh Bedi Independent Director 11713102 Non-Executive, Independent
Neha Kodan Company Secretary & Compliance Officer – Key Managerial Personnel

Who Owns the Stock? Shareholding Pattern

Category of Shareholder Number of Holders Total Shares Held % of Total Shares
Promoter Individuals (Pawan Chaudhary, Manu Chaudhary) 2 3,281,946 24.55%
Promoter Body Corporate (Sunev Pharma Solutions Pvt. Ltd.) 1 2,300,000 17.21%
Promoter Group Individuals 2 51 0.00%
Foreign Portfolio Investors (FPIs) 31 373,740 2.80%
Alternate Investment Funds (AIFs) 6 160,978 1.20%
Resident Individuals (Public) 17,312 5,934,236 44.39%
Bodies Corporate & LLPs 144 620,035 4.64%
Non-Resident Indians (NRIs) 393 217,941 1.63%
Clearing Members & HUF 510 340,811 2.55%
Investor Education and Protection Fund (IEPF) 1 134,041 1.00%
Escrow Account 1 3,200 0.02%
Total Shareholding 18,403 13,366,988 100.00%

🗺️ The Corporate Family Tree: Group Structure & Strategic Investments

Subsidiaries, Associates, & Joint Ventures (Form AOC-1)

Entity Name Relationship Country % Shareholding Turnover (₹ Crores) Profit / (Loss) After Tax (₹ Crores)
Venus Pharma GmbH Wholly Owned Subsidiary Germany 100.00% 26.84 3.84
Venus Pharma Kft Step-Down Subsidiary (via GmbH) Hungary 100.00% 0.00 (0.00)

Strategic Investments, Credit Facilities & Contingent Liabilities

The group holds mutual funds, debt-oriented instruments, and equity investments totaling ₹87.62 Crores under current and non-current financial assets. Outstanding working capital credit facilities stood at nil as the company operates debt-free. Contingent liabilities include pending tax demands of ₹0.60 Crores, disputed GST demands of ₹19.26 Crores, and capital commitments of ₹26.76 Crores.

🎯 The Strategic Outlook: Competitive Moats, Risks & Future Growth Plans

Competitive Advantages & Economic Moats

Venus Remedies possesses strong economic moats built on three decades of specialized sterile injectable manufacturing, extensive regulatory approvals (1,100+ global MAs across 100+ countries), and proprietary R&D platforms developed at VMRC. Holding two USFDA QIDP designations for critical anti-infective candidates (VRP-034 and VRP-048) places the company in an elite global tier for antimicrobial resistance research. Furthermore, its zero-debt balance sheet and proprietary digital automation tools (Project Hyperlink, ICD Online) provide operational agility and cost competitiveness.

What Could Go Wrong? Key Challenges & Business Risks

Key business risks include exposure to international regulatory scrutiny, potential price controls in domestic and export markets, volatility in active pharmaceutical ingredient (API) procurement costs, and foreign exchange fluctuations. Compliance failures in sterile manufacturing or delays in clinical pipeline progression could also impact long-term growth.

The Next Chapter: Growth, Order Pipeline & CapEx Initiatives

The company’s Mission 2030 strategy outlines ten institutional milestones centered on advancing anti-infective pipelines toward commercialization (including Phase 1 clinical trials for VRP-034), expanding manufacturing capacity via the greenfield Venus Industrial Park (VIP), deepening digital transformation through AI-first workflows, and scaling high-value specialty portfolios across regulated markets.

The Verdict: Strategic Outlook & Conclusion

FY 2026 marks a structural inflection point for Venus Remedies, characterized by zero debt, consolidated net profits crossing ₹100 Crores, robust operating cash generation, and the resumption of dividend payouts after a decade. With a reinforced balance sheet, proprietary R&D assets, and a scalable manufacturing footprint, the company is well-positioned for sustainable long-term value creation.

Frequently Asked Questions (FAQs) About Venus Remedies

Q1: What is the core business and product portfolio of Venus Remedies?

Venus Remedies is a research-driven pharmaceutical company specializing in complex injectable formulations, anti-infectives, oncology, and critical care therapeutics, supported by over 195+ commercial products and 1,100+ global marketing authorisations.

Q2: What were the key financial results of Venus Remedies for FY 2025-26?

For FY 2025-26, the company reported consolidated revenue from operations of ₹769.60 Crores, EBITDA of ₹159.86 Crores, and a Profit After Tax (PAT) of ₹102.79 Crores.

Q3: Who are the promoters and key managerial personnel leading the company?

The company is promoted by Pawan Chaudhary (Chairman, Managing Director & CFO) and Dr. (Mrs.) Manu Chaudhary (Joint Managing Director), alongside executive leaders Peeyush Jain, Ashutosh Jain, Akshansh Chaudhary, and Saransh Chaudhary.

Q4: Where are Venus Remedies’ manufacturing facilities and markets located?

The company operates manufacturing plants in Panchkula (Haryana) and Baddi (Himachal Pradesh), alongside European operations in Germany and Hungary, serving commercial markets across more than 100 countries worldwide.

Q5: What is the debt profile and financial strength of the company?

Venus Remedies maintains a landmark zero-debt balance sheet with robust liquidity, net operating cash flows of ₹155.77 Crores, and a total net worth (equity) of ₹663.75 Crores.

Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.

Official Site: https://www.venusremedies.com